Characteristics of HyQvia® - Ep. 7

Following the introduction to HyQvia® and the discussion on the onboarding of new patients in the previous two episodes, this episode focuses on the specific characteristics of HyQvia®. Together with nursing specialist Alina Ladariu we will explore the differences between intravenous immunoglobulin (IVIG) and facilitated subcutaneous immunoglobulin (fSCIG) treatments. In addition, Prof. Dr. med. Mike Recher provides insights into the physiological responses and outcomes following HyQvia® administration.

 

Moderator: Dr. med. Marcus Kühn, Specialist in Allergology and Clinical Immunology at Löwenpraxis, Lucerne           (website).

 

Guests:

  • Alina Ladariu, Nursing Specialist at Careformance (website).

  • Prof. Dr. med. Mike Recher, Head Physician at the University Center for Immunology at the University Hospital of Basel and Principal Investigator at the Department of Biomedicine at the University of Basel (website and website).

     

Resources and Links:

[1] Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé OA, Bernatowska E. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017 Nov 1;6(5):76-83. PMID: 29181272; PMCID: PMC5698561.

[2] Devonshire AL, Makhija M. Approach to primary immunodeficiency. Allergy Asthma Proc. 2019 Nov 1;40(6):465-469. Doi: 10.2500/aap.2019.40.4273. PMID: 31690396.

[3] Epland K, Suez D, Paris K. A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol. 2022 Sep 30;18(1):87. doi: 10.1186/s13223-022-00726-7. PMID: 36180928; PMCID: PMC9526304.

HyQvia® prescribing information: www.swissmedicinfo.ch

Cuvitru®prescribing information; www.swissmedicinfo.ch

Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.

C-APROM/CH/HYQ/0017_08/2024